News | May 14, 2025
Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
EBITDA before special items decreases to €4.08 billion (7.4%)
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
Gelhaus has a proven track record of driving business growth
The FDA issued Form 483 with one observation related to building and facility management
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
ekincare has raised a total funding of $22M since 2015 till date
Subscribe To Our Newsletter & Stay Updated
